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Abstract: Enormous progress has been made in the treatment of Parkinson’s disease (PD). As 
a result of advances in experimental therapeutics, many promising therapies for PD are emerg-
ing. Levodopa remains the most potent drug for controlling PD symptoms, yet is associated 
with signiﬁ  cant complications such as the “wearing off” effect, levodopa-induced dyskinesias 
and other motor complications. Catechol-o-methyl-transferase inhibitors, dopamine agonists 
and nondopaminergic therapy are alternative modalities in the management of PD and may be 
used concomitantly with levodopa or one another. The neurosurgical treatment, focusing on 
deep brain stimulation, is reviewed brieﬂ  y. Although this review has attempted to highlight 
the most recent advances in the treatment of PD, it is important to note that new treatments are 
not necessarily better than the established conventional therapy and that the treatment options 
must be individualized and tailored to the needs of each individual patient.
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Medical treatment of Parkinson’s disease
Enormous progress has been made in the treatment of Parkinson’s disease (PD) over the 
past half century, but levodopa remains the most potent drug for controlling PD symp-
toms (Jankovic 2008a). Prior to instituting medical therapy, a correct diagnosis of PD 
must be established and the level of impairment (motor, sensory, autonomic and mental) 
determined (Table 1). Each patient’s therapy is to be individualized, and diverse drugs 
other than levodopa are presently available. Among these are the dopamine agonists (DA), 
catechol-o-methyl-transferase (COMT) inhibitors and nondopaminergic agents (Figure 1). 
Head-to-head comparisons of drugs within classes are rare, and the differences that have 
emerged are related to the effects on motor ﬂ  uctuations, dyskinesias, on/off times and 
adverse effects of the speciﬁ  c agents within each class (Jankovic and Stacy 2007).
Levodopa
Levodopa is the most potent drug for controlling PD symptoms, particularly those related 
to bradykinesia (Jankovic 2002a). However, because levodopa therapy is frequently 
associated with motor complications, such as ﬂ  uctuations and dyskinesias, there is ongoing 
debate as to when in the course of PD it is most appropriate to initiate levodopa therapy 
(Stern 2004; Weiner 2004). The addition of carbidopa, a peripheral dopa decarboxylase 
inhibitor, enhances the therapeutic beneﬁ  ts of levodopa. In patients who are particularly 
sensitive to peripheral side effects such as nausea and vomiting, additional carbidopa 
(Lodosyn®) may be added to the conventional carbidopa/levodopa preparation.
A majority of patients treated with levodopa experience motor ﬂ  uctuations, 
dyskinesias or other complications after 5 years of treatment (Jankovic 2005). Since 
motor ﬂ  uctuations and dyskinesias are primarily related to the dose and duration 
of levodopa treatment (Schrag and Quinn 2000), most parkinsologists advocate Neuropsychiatric Disease and Treatment 2008:4(4) 744
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therapeutic strategies designed to delay the onset of levodopa 
therapy in order to delay the onset of levodopa-related motor 
complications (Jankovic 2002b).
The reported frequency of motor complications between 
the different studies varies, partly because of differences 
in definitions of the thresholds for recognizing motor 
complications (Marras and Lang 2003). One of the most 
common problems in patients taking levodopa is delayed 
onset of response after ingesting a dose of levodopa. A delay 
in achieving “on” state or a total response failure accounted 
for more than 60% of daily “off” time among 327 patients 
with advanced PD (Blindauer et al 2003).
There are different types of levodopa-induced dyskinesias, 
such as the “peak-dose dyskinesias”, “biphasic dyskinesias” 
and “wearing-off” dyskinesias (Fahn 2000; Jankovic 2002a). 
Besides cumulative dose and duration of levodopa treatment, 
there are other risk factors that should be considered before 
initiating levodopa therapy. Young-onset PD patients seem 
particularly likely to develop levodopa-induced dyskinesias. 
Certain genetic forms of PD, such as PARK2 and PARK8 
have been associated with a higher risk of levodopa-related 
motor complications (Lucking et al 2000; Schrag and 
Schott 2006).
There are three strategies designed to improve levodopa-
induced dyskinesias: 1) reduce the dosage of levodopa, 2) 
use drugs known to ameliorate dyskinesias, and 3) surgery. 
Several drugs, including amantadine, have been reported to 
improve levodopa-induced dyskinesias without necessitating 
the reduction in levodopa dosage (Verhagen Metman et al 
1999). The addition of a COMT inhibitor, MAO-I inhibitor or 
a dopamine agonist inhibitor may be used in the management 
of levodopa-induced motor complications (Jankovic et al 
2007) (Table 2). Other drugs with antidyskinetic effect 
include clozapine, ﬂ  uoxetine, propranolol, the cannabinoid 
Table 1 Guidelines for treatment of Parkinson’s disease
Ensure correct diagnosis
Determine level of motor, mental, sensory, autonomic and other 
impairments
Educate the patient about the disease and importance of mental and 
motor activity
Consider putative neuroprotective agent(s)
Select the most appropriate symptomatic therapy, targeted to the most 
troublesome symptoms
Consider surgery (DBS) in patients who are levodopa-responsive 
but their levodopa-related motor complications cannot be managed 
adequately with medication adjustments
Therapy must be customized and tailored to the individual needs of the 
patient
Abbreviation: DBS, deep brain stimulation.
Figure 1 Pharmacologic treatment options available for PD.
Abbreviations: BBB, blood-brain barrier; COMT, catechol-O-methyl-transferase; DA, dopamine; L-DOPA, 3,4 dihydroxy-L-phenylamine; HVA, homovanillic acid; 3-MT, 
3-methoxytramine; MAO, monoamine oxidase.Neuropsychiatric Disease and Treatment 2008:4(4) 745
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receptor agonist nabilone, and ﬁ  pamezole. Some of the 
new antiepileptic drugs are being investigated as potential 
therapies for levodopa-induced dyskinesias. For example, 
levetiracetam (Keppra®) was found to signiﬁ  cantly reduce 
levodopa-induced dyskinesias in MPTP-lesioned marmosets 
(Hill et al 2003). In patients with severe motor ﬂ  uctuations, 
apomorphine, a subcutaneous dopamine agonist, may be used 
as rescue therapy (Pietz et al 1998).
The “wearing off” effect, the most frequent form of 
motor ﬂ  uctuation, appears to be related to the shortening of 
levodopa’s half-life in the striatum as a result of impaired 
capacity to store and buffer the striatal concentration of 
levodopa, due to a loss of striatal dopaminergic terminals 
(Verhagen Metman et al 2000). Amantadine, a NMDA recep-
tor blocker, has been found to ameliorate motor ﬂ  uctuations 
in parkinsonian animals and patients (Verhagen Metman et al 
2000; Pereira et al 2005). In patients with “wearing-off” and 
“on-off” phenomena, the response to apomorphine, a post-
synaptically acting dopamine agonist, is shortest and steepest 
in patients with the most severe motor ﬂ  uctuations (Manson 
et al 2002). In addition, apomorphine is capable of sustaining 
a long-duration response (Nutt and Carter 2000).
Strategies designed to prolong and smooth out the thera-
peutic concentrations of levodopa-related motor ﬂ  uctuations 
usually improve by increasing the frequency of administra-
tion of levodopa. Slow-release preparations of levodopa, 
such as Sinemet® CR, offer the possibility of “smoothing 
out” clinical ﬂ  uctuations by slowly releasing the levodopa 
from a special matrix. In addition to prolonging the “on” 
time, smoothing out the wearing off response and reducing 
the total number of doses and tablets taken per day, Sinemet 
CR also seems helpful in alleviating troublesome nighttime 
rigidity, thus allowing patients to have more restful nights 
and better nighttime mobility. Potential disadvantages of 
Sinemet CR over standard preparations include delayed 
or poor response after the morning dose (absence of the 
“morning kick”) and an exacerbation and prolongation of 
peak-dose dyskinesias.
Continuous dopaminergic stimulation (CDS) has been 
advocated as a strategy to prevent or control levodopa-
related motor ﬂ  uctuations presumably associated with 
pulsatile stimulation associated with levodopa dosing, 
although this concept has been challenged (Nutt 2007). CDS 
methods include duodenal infusions of levodopa, oral solu-
tions of levodopa made by dissolving it with ascorbic acid 
in water, a dispersible form of levodopa (Etilevodopa®), 
subcutaneous or intramuscular injections of levodopa ethy-
lester, and intravenous (and intraventricular) administration 
of levodopa methyl ester, but the latter methods are not 
practical and have not translated into clinical practice 
(Stocchi et al 2005).
COMT inhibitors
Another strategy to prolong DA response utilizes the inhi-
bition of COMT by drugs such as entacapone (Comtan®). 
Entacapone, because of its short half-life, requires frequent 
administration (200 mg, up to 8 times per day); most patients 
take entacapone with each dose of levodopa (Schrag 2005). 
Tolcapone (Tasmar®), another COMT inhibitor, is rarely used 
because of a report of three cases of acute fulminant liver 
failure (Assal et al 1998; Olanow et al 2000) leading to black 
box warning and intensive monitoring requirements (Ellison 
1998). The safety and tolerability of adjunctive tolcapone ini-
tiated simultaneously with levodopa was recently evaluated, 
with a focus on changes in liver transaminases and potential 
hepatotoxicity (Lees et al 2007). In this study, 677 levodopa-
naive patients in early stages PD were randomized to receive 
placebo or tolcapone 100 mg three times daily, added to 
standard doses of levodopa plus carbidopa or benserazide. 
In both placebo and tolcapone treated patients, there were 
mild elevations in transaminase levels, less than 3 times the 
upper limit of normal (ULN), whereas potentially serious 
increases of up to or over 3 times the ULN were infrequent 
(1.8% in the tolcapone treated group compared to 1.2% in 
those treated with placebo, p = 0.5), supporting the safe 
use of tolcapone in selected patients who are monitored for 
potential liver toxicity. According to current FDA recom-
mendations (1998), the monitoring should include serum 
alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST), prior to starting treatment with tolcapone. These 
enzymes should be monitored every two weeks for the ﬁ  rst 
year, every 4 weeks for the next 6 months and then every 
Table 2   Antidyskinesia drugs
Amantadine (NMDA inhibitor)
Buspirone (G-HT1A agonist)
Fluoxetine (SSRI)
Propranolol
Clozapine (D4/D1 antagonist, 5-HT2 antagonist)
Olanzapine (D1/D2/D4 antagonist)
Naloxone (opioid antagonist)
Nabilone (cannabinoid receptor agonist)
Sarizotan (D4 and 5HT1A agonist)
Istradefylline (KW-6002, adenosine A2A antagonist)
Fipamezole (JP-1730, alpha-adrenergic antagonist)
Levetiracetam (Keppra®)
Talampanel (AMPA antagonist)
Idazoxan (alpha-2 antagonist)Neuropsychiatric Disease and Treatment 2008:4(4) 746
Jankovic and Aguilar
8 weeks thereafter. Prior to increasing tolcapone, ALT and 
AST levels should be monitored and subsequently scheduled 
at the above mentioned frequency.
Theoretically, the COMT inhibitors have an advantage 
over Sinemet CR in that they do not delay the absorption of 
levodopa and, although they increase the levodopa plasma 
concentration, they do not increase the time to reach the peak 
concentration or the maximal concentration of levodopa 
(Ruottinen and Rinne 1998). While this pharmacologic action 
of the COMT inhibitors may prolong the “on” time without 
markedly increasing dyskinesias, most studies do report 
increased levodopa-induced dyskinesia in patients taking 
COMT inhibitors, requiring a substantial (25%) reduction 
in daily levodopa dosage. Thus patients, with and without 
ﬂ  uctuations, beneﬁ  t from the addition of entacapone to their 
levodopa treatment. Except for nausea and increased dyskine-
sia, entacapone is usually well tolerated. Early intervention, 
such as phone calls to the patients, clearly improves compli-
ance, and this translates into not only increased “on”-time 
and reduced levodopa dosage, but also further improvement 
in quality of life measures (Grandas et al 2007).
In 2003, the US FDA approved triple combination tablets 
(Stalevo®) containing carbidopa, levodopa, and entacapone 
for end-of-dose wearing off. In a randomized, crossover 
study of 132 healthy subjects, the levodopa AUC (area 
under the curve) was essentially the same when used in the 
triple combination versus when administered separately, 
indicating equivalent pharmacokinetics (Heikkinen et al 
2003; Hauser 2004).
Dopamine agonists
The possibility that levodopa is neurotoxic, and that the 
onset of levodopa-induced complications may be related 
to the duration of treatment, are the two most important 
reasons why many experts recommend delaying levodopa 
therapy until parkinsonian symptoms clearly begin to 
interfere with patients’ functioning and normal lifestyle. In 
order to delay or prevent levodopa-induced complications 
many parkinsonologists recommend using DA agonists as 
the initial or early form of dopaminergic therapy (Jankovic 
2000). When used as monotherapy, DA agonists provide 
only modest improvement in parkinsonian symptoms, but 
the improvement may be sufﬁ  cient to delay the introduction 
of levodopa by several months or years.
Dopamine agonists (DA) exert their pharmacologic 
effect by directly activating DA receptors, bypassing the 
presynaptic synthesis of DA. Experimental and clinical 
studies have provided evidence that activation of the 
D2 receptors is important in mediating the beneficial 
antiparkinsonian effects of DA agonists, but concurrent D1 
and D2 stimulation is required to produce optimal physi-
ological and behavioral effects (Brooks 2000) (Table 3). In 
contrast to the traditional DA agonists (bromocriptine and 
pergolide), pramipexole and ropinirole are nonergolines 
and therefore are expected to have a lower risk of com-
plications such as peptic ulcer disease, vasoconstrictive 
effects, erythromelalgia, pulmonary and retroperitoneal 
ﬁ  brosis, and valvular heart disease (Tintner et al 2005; 
Roth 2007; Zanettini et al 2007). Pramipexole often causes 
dose-dependent and idiosyncratic peripheral edema (Tan 
and Ondo 2000). Because of the potential for valvular heart 
disease, the ergot dopamine agonists have been essentially 
discontinued from medical practice.
Pramipexole has been shown to be a safe and effec-
tive drug when used as monotherapy in early stages of PD 
(Parkinson Study Group 2002) and in mild to moderate PD 
(Weiner et al 2001). In addition to its beneﬁ  cial effects on 
the PD clinical symptoms and levodopa sparing (about 25% 
reduction in daily levodopa dosage), pramipexole has been 
demonstrated to possibly exert a neuroprotective effect and 
to enhance neurotrophic activity in mesencephalic dopami-
nergic cultures (Zou et al 1999).
Ropinirole has been also demonstrated to be effective in 
early PD (Korczyn et al 1999; Rascol et al 2000). In clinical 
practice, dosages high as 24 mg may be needed to achieve 
optimal response (Korczyn et al 2002). Some studies have 
shown that dosages of ropinirole as high as 35 mg per day are 
safe and provide additional beneﬁ  ts in patients with advanced 
PD (Cristina et al 2003). In addition to increasing dosages 
of DA agonists, several studies have explored the potential 
for synergistic effects of combined DA agonist therapy. For 
example, Stocchi et al (2003) found in an open label study 
that the addition of cabergoline to other DA agonists signiﬁ  -
cantly improved the UPDRS scores and motor ﬂ  uctuations 
and that dual DA agonist therapy may be useful in patients 
with PD with or without levodopa.
Meta-analysis comparing adverse effects of ropinirole 
to pramipexole showed that there was no signiﬁ  cant differ-
ence in the risk of dizziness, nausea, or hypotension with 
either drug individually or in combination when compared 
with levodopa (Etminan et al 2003). The use of ropinirole 
appeared to be associated with a higher risk of hypotension 
and somnolence as compared with pramipexole when com-
pared with placebo and the use of pramipexole appeared to 
be associated with a higher risk of hallucinations than use of 
ropinirole when compared with placebo.Neuropsychiatric Disease and Treatment 2008:4(4) 747
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Apomorphine is a water soluble DA and is consequently 
suitable for intravenous, subcutaneous, sublingual, or 
intranasal administration (Ondo et al 1999a; Poewe and 
Wenning 2000). Subcutaneous injections or continuous infu-
sions have been found useful even in advanced PD by reduc-
ing the “off” time without necessarily increasing dyskinesias 
(Pietz et al 1998). In our study of sublingual apomorphine in 
patients with advanced PD, we found a marked reduction in 
the UPDRS score, an increase in “on” time, an increase in 
tapping speed, and a signiﬁ  cant reduction in levodopa dosage 
(Ondo et al 1999b). Several reports have also suggested that 
apomorphine may exert a neuroprotective effect in MPTP 
animals and other models (Grünblatt et al 1999). A formula-
tion of a novel highly selective D2 DA agonist, rotigotine, 
in a silicone based transdermal system (4.5–18 mg/patch) 
approved by the FDA in 2007 for the treatment of early PD 
(Jankovic et al 2007; Watts et al 2007), has also been found 
to be effective in the treatment of advanced PD (LeWitt 
et al 2007). The improvement in the UPDRS appears to be 
dose-dependent, and the drug was well tolerated at plasma 
levels that produce clinical improvement at doses of 8.4 to 
67 mg, except for some side effects usually associated with 
DA agonists, such as somnolence, nausea, vomiting, and 
occasional skin irritation (Parkinson Study Group 2003; 
Poewe and Leussi 2005). Rotigotine (Neupro®) is available 
as 2 mg, 4 mg, and 6 mg per day patches. In March 2008, 
Schwarz Pharma, the German pharmaceutical company 
who developed the drug, now marketed by UCB Pharma, 
announced their decision to withdraw the drug from the US 
market due to formation of crystals in the patches, which 
interferes with the absorption of the drug into the skin. The 
company is currently working diligently to correct the prob-
lem and is consulting with the FDA to make sure that future 
supplies meet the highest quality standards.
Although levodopa is clearly the most effective drug for 
the treatment of motor symptoms of PD, whether levodopa 
should be used in early stages of PD or delayed until later 
in the disease process has been the subject of many debates. 
This debate is partly fueled by the observation that in patients 
with early onset PD (particularly before the age of 40), their 
disease course is longer and they have a particularly high risk 
for developing motor ﬂ  uctuations and dyskinesias. The argu-
ment to delay levodopa therapy is chieﬂ  y supported by studies 
showing that early use of dopamine agonists delays the need 
for levodopa and thus delays the onset of levodopa-related 
motor complications, particularly motor ﬂ  uctuations and 
dyskinesias, and that dopamine agonists may exert favorable 
disease-modifying effects (Le and Jankovic 2001; Parkinson 
Study Group 2002; Simpkins and Jankovic 2003; Whone et al 
2003). The strategy of early initiation of levodopa is supported 
by studies that indicate that levodopa provides a longer period 
of superior motor control, slower progression of disability, 
longer life expectancy (Lees et al 2001; Rajput et al 2002), 
and no difference in “clinically relevant” dyskinesias between 
levodopa and dopamine agonist treated patients (Lees et al 
2001). There is a lower incidence of hallucinations, vomiting, 
and leg edema with levodopa as compared to dopamine ago-
nists (Whone et al 2003), and no in vivo evidence of levodopa 
toxicity (Le and Jankovic 2001). Since younger patients seem 
to be at a higher risk of levodopa-related motor complications, 
delaying levodopa therapy seems to be a prudent practice at 
least in this population of PD patients.
Nondopaminergic therapy
In addition to the dopaminergic drugs, nondopaminergic 
drugs, such as the anticholinergics and amantadine, may 
provide satisfactory symptomatic relief in early phases of 
anti-PD therapy. The anticholinergic drugs, such as trihexy-
phenidyl or benztropine, are particularly useful in younger 
patients who are primarily bothered by tremor. Although 
quite effective, their usefulness is limited by the anticholin-
ergic side effects such as cognitive impairment, dry mouth 
and urinary symptoms. The tricyclics are often used not only 
because of their antidepressant effects, but also because of 
their anticholinergic properties. Mirtazapine (Remeron®), a 
novel antidepressant that enhances noradrenergic and seroto-
nergic transmission and acts as a presynaptic alpha-2, 5HT2, 
and 5HT3 receptor antagonist, has been reported to improve 
Table 3 Pharmacology of dopamine agonists
Parameter  Bromocriptine   Pergolide   Ropinirole   Pramipexole   Rotogotine
 parlodel  permax  requip  mirapex  neupro
DA receptors  D2  D3  D3  D2  D1  D3  D2  D3  D2  D3  D2  D1
Structure Ergot  Ergot  Nonergot  Nonergot  Nonergot
T ½ (hours)  3–8  27  7  13  6.8
Protein binding (%)  95  90  30  20  92
Liver metabolism  +  +  +  −  +Neuropsychiatric Disease and Treatment 2008:4(4) 748
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rest tremor and levodopa-induced dyskinesia (Pact and Giduz 
1999). Istradefylline, a novel adenosine antagonist, has been 
also reported to provide modest beneﬁ  t in PD patients with 
levodopa-related motor complications (Jankovic 2008b). 
Rapid eye movement (REM) sleep behavior disorder (RBD), 
which may be the initial manifestations of Parkinsonism, may 
respond to night-time clonazepam. Drooling (sialorrhea), 
one of the most embarrassing symptoms of PD caused by 
impaired swallowing, has been successfully treated with 
botulinum toxin injections (Bhatia et al 1999; Pal et al 1999; 
Shefﬁ  eld and Jankovic 2007).
The most important principle in the management of PD 
is to individualize therapy and to target the most disabling 
symptoms. The selected therapy should be based on scientiﬁ  c 
rationale and designed not only to control symptoms, but 
also to slow the progression of the disease (Figure 2). Since 
younger patients are likely to require dopaminergic therapy 
for longer time and are at increased risk for the development 
of levodopa complications, levodopa sparing strategies, such 
as the use of MAO inhibitors and DA agonists, are even more 
critical in this population (Jankovic 2000). Certain symptoms 
of PD, such as dysarthria, dysphagia, freezing and other 
“axial” symptoms, usually do not respond to dopaminergic 
therapy and may be mediated by nondopaminergic systems 
(Bonnet 2000; Kompoliti et al 2000). It is very likely that with 
better understanding of the mechanisms of neurodegenera-
tion, novel and more effective therapeutic strategies will be 
available in the near future.
Adjunctive therapy
While neuroprotective strategies slow or halt the progres-
sion of the disease, these strategies must be implemented 
early (Schapira 2004). Clinically relevant effects of putative 
neuroprotective agents are difﬁ  cult to measure and so more 
and more studies utilize not only clinical ratings, but also 
ancillary techniques, such as 18F-L-DOPA PET and 123I 
β-CIT SPECT, to longitudinally measure the progression 
of nigrostriatal degeneration.
The ﬁ  nding that deprenyl (selegiline) prevents MPTP-
induced Parkinsonism has stimulated interest in antioxida-
tive therapy as a means of retarding progression of PD and 
other neurodegenerative diseases. In the largest clinical trial 
designed to address the potential protective effects of sele-
giline, “Deprenyl and Tocopherol Antioxidative Therapy of 
Parkinsonism” (DATATOP), the outcomes of treatments with 
deprenyl, alpha-tocopherol (vitamin E) and a combination of 
these putative antioxidants in comparison to a placebo were 
compared. The results showed that deprenyl-treated patients 
reached the end-point 9 months after the group treated with 
placebo or tocopherol. The waning of the effects of selegiline 
on delaying end-point after the ﬁ  rst year, coupled with slight 
but signiﬁ  cant improvement in motor performance after 
initiation of selegiline and slight (nonsigniﬁ  cant) worsening 
after 1-month washout, has been used as an argument in favor 
of predominantly symptomatic rather than protective effect. 
In a follow up study, levodopa treated PD patients who have 
been taking selegiline for 7 years, compared to those who 
were changed to placebo after 5 years, showed signiﬁ  cantly 
slower decline, less wearing off, on-off motor ﬂ  uctuations, 
and less freezing, but more dyskinesias (Shoulson et al 
2002). This is consistent with another study of the same 
patient population, which showed that patients randomized 
to selegiline had a lower risk of freezing than those assigned 
to placebo (Giladi et al 2001).
In clinical studies, rasagiline, a selective, irreversible 
MAO B inhibitor, provides a modest beneﬁ  t as an adjunc-
tive therapy in PD patients experiencing levodopa related 
motor ﬂ  uctuations. A double-blind, placebo-controlled trial 
showed that after a 10-week treatment with rasagiline, 12 of 
43 (28%) of patients had an improvement in total UPDRS 
score of 30% or greater, compared with none in the placebo 
group (p  0.05) (Stern et al 2004). In an 18-week, double-
blind trial of 687 patients randomized to receive once-daily 
rasagiline, entacapone (with each dose of levodopa), or 
placebo (the LARGO trial), both rasagiline and entacapone 
reduced “off” time by 1.2 hours as compared with placebo 
(0.4 hour reduction, p  0.0001). The mean daily dose of 
levodopa was reduced on rasagiline and on entacapone, and 
was increased on placebo (Rascol et al 2005). Other vari-
ables showed that rasagiline was superior to placebo and to 
entacapone in reducing UPDRS motor score, and at least as 
effective as entacapone in reducing “off” time compared to 
baseline (Parkinson Study Group 2005).
In one study of 80 patients with early PD, Shults and 
colleagues (2002) found that in comparison to placebo, 
1200 mg of CoQ10 was associated with a slower decline 
in UPDRS and a positive trend in decline UPDRS decline 
favoring CoQ10. In this study, patients never previously 
treated with L-DOPA were randomized to receive placebo or 
one of three doses of CoQ10: 300, 600, or 1200 mg/day. In 
addition, they were also receiving 300 IU vitamin E, which 
was thought to act as a carrier of CoQ10 across the blood-
brain barrier. The patients were followed for 16 months or 
until they required L-DOPA. The drug was found to be well 
tolerated, and there was no difference in adverse effects 
between CoQ10 and placebo. When compared to baseline, Neuropsychiatric Disease and Treatment 2008:4(4) 749
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the group receiving placebo deteriorated by 12 points in the 
UPDRS, whereas patients receiving 1200 mg deteriorated 
by only 6.7 points. Furthermore, patients receiving CoQ10 
had on the average 44% less decline in mental function, 
movement and ability to perform daily living tasks than the 
placebo group. This difference was statistically signiﬁ  cant 
only for the 1200 mg/day group, but there was no difference 
between placebo and the lower dose groups. Treatment did 
not delay the disability severe enough to require L-DOPA. 
The study was highly suggestive, yet was not deﬁ  nitive. 
There is no evidence that vitamin supplements, includ-
ing vitamin C and E, or carotenoids reduce the risk of PD 
(Zhang et al 2002). Further studies are needed to determine 
whether CoQ10 and other quinines, such as idebenone, may 
serve as either substitutive electron carriers or antioxidant 
compounds in disorders with known or suspected mitochon-
drial dysfunction.
Antiglutamatergic drugs
Interactions between dopamine and glutamate in striatal 
medium spiny neurons have been found to play an impor-
tant role in PD, and there is considerable theoretical and 
experimental support for the use of glutamate antagonists 
as potential neuroprotective drugs (Chase and Oh 2000). 
Several studies have demonstrated that the neuronal activity 
is increased in the subthalamic nucleus (STN) and in the 
internal segment of globus pallidum (GPi) of parkinsonian 
animals and humans (Obeso et al 2000a). Since STN pro-
vides excitatory, glutamatergic input to GPi, glutamate 
inhibition would be expected to improve Parkinsonism. 
Some studies indeed have shown that N-methyl-D-aspartate 
(NMDA) antagonists prevent the selective toxicity of 
MPP+ and that an ablation of STN attenuates the loss of 
DA neurons in rats exposed to the mitochondrial toxin 
3-nitroproprionic acid (3-NP) or the catecholamine toxin 
(6-OHDA) (Nakao et al 1999). Certain anticholinergic 
drugs and amantadine posses NMDA-blocking properties 
and amantadine have been shown to not only amelio-
rate parkinsonian symptoms, but also to improve motor 
ﬂ  uctuations and levodopa induced dyskinesias (Verhagen 
Metman et al 1999; Luginger et al 2000).
Future therapies
One particularly promising therapeutic and potentially 
neuroprotective approach involves the use of neurotrophic 
factors, such as neurturin (NTN) (Kordower et al 2006) 
and the glial cell-line-derived neurotrophic factor (GDNF) 
(Gash et al 1998). These trophic factors have been reported 
to enhance the survival of midbrain dopaminergic neurons 
in vitro and to rescue degenerating neurons in vivo. These 
encouraging observations have led to a pilot human trial of 
GDNF administered by an implanted intracerebroventricular 
Figure 2 Treatment guidelines for the progressive stages of Parkinson’s disease.
Abbreviations: COMT, catechol-o-methyl-transferase; DBS, deep brain stimulation; MAO, monoamine oxidase.Neuropsychiatric Disease and Treatment 2008:4(4) 750
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catheter in patients with moderately advanced PD conducted 
in several centers in North America. However, because of 
lack of observed efﬁ  cacy and frequent occurrence of nausea, 
anorexia, tingling (L’hermitte’s sign), hallucinations, and 
depression, these trials were suspended (Nutt et al 2003). 
In a one-year follow-up of ﬁ  ve patients with PD in whom 
GDNF was continuously infused directly into the putamen, 
there were no serious clinical side effects, a 39% improve-
ment in the off-medication motor sub-score of the UPDRS 
and a 61% improvement in the activities of daily living 
sub-score. Furthermore, levodopa-induced dyskinesias were 
reduced by 64% and, in contrast to fetal implants (see below) 
there were no off dyskinesia. This clinical improvement was 
accompanied by a 28% increase in putamen PET F-DOPA 
uptake (Gill et al 2003). Results from a recently completed 
multicenter trial, however, show no beneﬁ  t from GDNF (Lang 
et al 2006) and further studies have been suspended because 
of evidence of cerebellar toxicity in experimental primates.
CERE-120 is an adeno-associated virus type 2 (AAV2) 
vector encoding human NTN (AAV2-NTN). In a recent open 
label trial, 12 patients with advanced PD were stereotactically 
administered bilateral intraputaminal CERE-120 (Marks et al 
2006). Two doses were evaluated, with six patients in each 
cohort. UPDRS and off-medication motor scores improve-
ment of 20% and 25%, respectively, were observed at both 
three and six months in the low dose cohort. Improvement in 
the total off-medication motor scores was approximately 26% 
and 22%, respectively, at three months in the high dose cohort. 
Rigidity and bradykinesia measurements showed the greatest 
improvement, off-time was reduced by 27% and “on”-time 
was doubled without dyskinesias through six months in the low 
dose cohort, with similar trends in the high dose cohort. The 
intraputaminal administration of CERE-120 was well tolerated. 
Ongoing double-blind clinical trials are under way to determine 
the efﬁ  cacy and safety of CERE-120 in patients with PD.
In addition to neurotrophic factors, other therapeutic pos-
sibilities currently being investigated include retinal pigment 
epithelial cells (hRPE). These cells, located in the inner layer 
of neural retina, produce levodopa. When attached to cross 
linked gelatin microcarriers (Spheramine®) and implanted 
stereotactically into the striatum, the cells have improved 
parkinsonian symptoms in rodents, nonhuman primates and 
parkinsonian patients. A pilot, open label study of 6 patients 
showed 48% improvement in the UPDRS motor score after 
implantation in the most affected postcommissural putamen. 
All patients tolerated the implantation of Spheramine well 
and demonstrated improvement. At 6, 9, and 12 months post-
operatively, the mean UPDRS-Motor score “off”, the primary 
outcome measure, improved 33%, (n = 6), 42% (n = 6), and 
48% (n = 3), respectively. No "off-state" dyskinesias were 
observed (Watts et al 2003). The 48% improvement was 
maintained at 24 months (Stover et al 2005a).
Treatment of neurobehavioral features
Treatment of cognitive deﬁ  cits associated with PD is as chal-
lenging as the treatment of Alzheimer’s disease and other 
dementias. While the general assumption has been that cogni-
tive deﬁ  cits are a feature of late-stage PD, clinically inapparent 
cognitive changes on neuropsychiatric testing may be found 
(Williams-Gray et al 2006). With the introduction of cholin-
esterase inhibitors such as donepezil (Aricept®), rivastigmine 
(Exelon®), and galantamine (Reminyl®,) and the NDMA 
antagonist memantine (Namenda®) (Reisberg et al 2003), it is 
possible that cognition, orientation and language function will 
improve, and that such improvement will lead to a meaningful 
improvement in function. Both donepezil and rivastigmine 
improve cognition to the same effect, but donepezil is bet-
ter tolerated (Wilkinson et al 2002). The largest and best-
designed study of rivastigmine in dementia associated with 
PD involved 541 patients enrolled in a 24-week randomized, 
multicenter, double-blind clinical trial (Emre et al 2004). The 
patients had a relatively mild dementia (MMSE 10–24), with 
onset of dementia about 2 years after onset of PD symptoms. 
The mean ADAS-cog score, the primary efﬁ  cacy variable, 
improved by 2.1 points in the rivastigmine group, compared 
to 0.7 in the placebo group (p  0.001), and the MMSE 
improved by 0.8 in the rivastigmine group and worsened by 
0.2 in the placebo group (p = 0.03). At the end of the study, 
55.5% were receiving 9 to 12 mg. The adverse effects that 
were signiﬁ  cantly more frequent in the rivastigmine group 
were nausea, vomiting, dizziness, and tremor.
Rivastigmine should be started at 1.5 mg BID and 
increased at 4-week intervals to 3 mg BID and eventually to 
6 mg BID. This slow titration is designed to prevent potential 
side effects such as nausea, vomiting, agitation and weight 
loss. In a recent database study conducted by the VA, over 
4.5 million subjects were reviewed, with analysis restricted 
to those patients over 65 years who did not have a prior 
diagnosis of Alzheimer’s or Parkinson’s disease. The use 
of simvastatin was associated with a reduction in incident 
dementia; and after adjusting for cardiovascular disease, 
hypertension, diabetes and the use of neuroleptics, simv-
astatin was also observed to be associated with a reduced 
incidence of PD (Wolozin et al 2007).
In addition to motor side effects related to levodopa 
therapy, many PD patients experience a variety of psychiatric Neuropsychiatric Disease and Treatment 2008:4(4) 751
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reactions, particularly psychosis with agitation, delusions, 
paranoid beliefs and hallucinations (Fénelon et al 2000). In PD 
patients with new symptoms of confusion or psychosis, factors 
unrelated to PD and PD-related treatment must be identiﬁ  ed 
prior to modifying therapies or adding antipsychotics. Psy-
chotic symptoms can be controlled by reducing the dosage of 
dopaminergic drugs (levodopa, dopamine agonists) and elimi-
nating all other drugs that are not absolutely essential. Borek 
and colleagues (2007) suggested eliminating anticholinergics 
ﬁ  rst, followed by amantadine, monoamine oxidase inhibitors, 
dopamine agonists, COMT inhibitors, then reducing the 
amount of levodopa. Atypical antipsychotics offer the best 
strategy for controlling drug-induced psychosis without the 
need to adjust the dosage of dopaminergic drugs (Friedman 
and Factor 2000). While quetiapine has been used successfully 
based on open label ﬁ  ndings, two double-blind studies did not 
ﬁ  nd signiﬁ  cant differences in the management of psychosis 
in patients with PD when compared with placebo (Ondo et al 
2005a; Rabey et al 2007). Other atypical antipsychotics such 
as risperidone, olanzapine, ziprasidone and aripiprazole have 
been found to worsen motor performance without demonstrat-
ing statistically signiﬁ  cant improvement of dopamine-induced 
psychosis (Rich et al 1995; Breier et al 2002; Ondo et al 
2002; Friedman et al 2006). This is in contrast with studies 
where quetiapine (Mancini et al 2004; Merims et al 2006) 
and ziprasidone (Gomez-Esteban et al 2005) improved the 
psychotic symptoms without causing variation in their motor 
performance. Treatment with atypical neuroleptics, such as 
clozapine, has been associated with improved prognosis 
(Factor et al 2003). The use of clozapine has been limited 
due to the potential to cause agranulocytosis, which is an 
idiosyncratic reaction, and not dose-related (Fernandez et al 
2003). Cholinesterase inhibitors such as donepezil (Fabbrini 
et al 2002) and rivastigmine (Reading et al 2001) have been 
found to be beneﬁ  cial, without worsening of the UPDRS, in 
small, open label studies.
Depression has an estimated prevalence of 40%–50%, 
and is one of the most common behavioral disturbances in PD 
(Tandberg et al 1996; Zesiewicz et al 1999). It may present 
at any stage of the disease, and may precede the appear-
ance of motor symptoms (Cummings 1992). Risk factors 
for PD-related depression include female sex, a history of 
depression, early-onset PD (ie, before the age of 55 years) 
and “atypical” Parkinsonism (eg, prominent akinesia/rigidity 
or extensive vascular disease) (Weintraub et al 2007). The 
subthalamic nucleus has been implicated in mood disorders 
in PD patients, as deep brain stimulation (DBS) has been 
found to have antidepressant, depressive and mania-inducing 
effects (Takeshita et al 2005). Because depressive symptoms, 
such as ﬂ  at affect, anxiety, cognitive impairment, fatigue, 
weight loss, and sleep disturbances often overlap with those 
of PD, diagnosis is often under-recognized. In a cohort of 
over 400 newly diagnosed patients with PD, followed for an 
average of 14.6 months, 27.6% (114) screened positive for 
depression. Of these, 40% were neither treated nor referred 
for psychiatric evaluation (Ravina et al 2007). The same 
study found depression to be a signiﬁ  cant predictor of more 
impairment in activities of daily living and increased need for 
symptomatic therapy of PD. Given the effects of depression 
on motor function and quality of life, prompt recognition 
and early treatment are integral aspects in the management 
of PD. Tricyclic antidepressants, while not necessarily the 
drug of ﬁ  rst choice (due to their side effect panel), may be 
considered in the treatment of depression in PD (Miyasaki 
et al 2006). The anticholinergic properties of the TCAs may 
be helpful in PD patients with drooling, overactive bladder 
and insomnia. Selective serotonin reuptake inhibitors (SSRIs) 
have been recommended as ﬁ  rst-choice antidepressants in 
PD considering their tolerability, and acceptable side effect 
proﬁ  le and drug-drug interactions (Borek et al 2007). There 
are some conﬂ  icting data whether the selective serotonin 
receptor inhibitors (SSRIs) exacerbate Parkinsonism, but a 
study of 30 PD patients, (Ceravolo et al 2000) found parox-
etine, one of the typical SSRIs, at doses of 20 mg/day, to be 
safe and effective in the treatment of depression associated 
with PD. Caution must be exercised when using selegiline 
in combination with SSRIs and TCAs, as there is a small but 
increased risk of developing a serotonin syndrome. Anti-
parkinsonian medications, such as selegiline (Allain et al 
1991; Baronti et al 1992), bromocriptine (Jouvent 1983), per-
golide (Rektorova et al 2003) and pramipexole (Barone et al 
2003) have been reported to have antidepressant effects.
Like depression, anxiety has been reported in up to 40% of 
PD patients (Stein et al 1990; Vasquez et al 1993); similarly, 
anxiety may precede the appearance of motor symptoms by 
many years, and usually before onset of depression (Shiba 
et al 2000). The most common anxiety disorders in PD are 
panic disorder, generalized anxiety disorder and social phobia 
(Vasquez et al 1993; Richard 2005). Anxiety has been reported 
to occur in patients experiencing “on-off” states, particularly 
the “off” period (Stein et al 1990; Vasquez et al 1993). In these 
instances, adjustment of antiparkinsonian medications may 
be effective in managing anxiety. SSRIs, with their favorable 
side effect proﬁ  le, are used as ﬁ  rst-line treatment; onset of 
anxiolytic effects usually occurs between 2 and 4 weeks, with 
dose adjustment after 1 month (Borek et al 2007).Neuropsychiatric Disease and Treatment 2008:4(4) 752
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Apathy is characterized by loss of motivation, and 
diminished goal-directed behavior. It affects over 10% of 
PD patients, and is believed to be due to prefrontal lobe 
dysfunction (Starkstein et al 1992; Luck et al 2002). Apathy 
is independent of depression and anxiety, being mainly 
determined by cognitive impairment (Dujardin et al 2007). 
With no known treatment, antidepressants are given in the 
hope that the apathy is a component of a depressive syndrome 
(Borek et al 2007).
Impulse control disorders (ICDs) have been described in 
PD patients treated with dopamine agonists (Voon 2004), and 
consist of punding, compulsive gambling, compulsive shopping, 
compulsive eating, and hypersexuality. The ﬁ  rst impulsive 
behavior described in patients with PD was punding and was 
initially attributed to treatment with levodopa (Friedman 1994). 
Punding behavior, an intense fascination with repetitive, aimless 
behavior, as ﬁ  rst described in amphetamine and cocaine abuse, 
is presumed to be secondary to dopaminergic excess. It has since 
been reported to occur in PD patients treated with dopamine 
agonists (Kurlan 2004). The incidence of punding varies from 
1.4% to 14% (Evans et al 2004; Miyasaki et al 2007). Evans 
and colleagues (2004) noted that punding in patients with PD 
occurred rather frequently and was associated with the use 
of either or both L-DOPA and dopamine agonists. They also 
suggested that requirements for large doses of dopaminergic 
therapy, frequent rescue doses and the use of rescue medications 
overnight should raise suspicion and prompt queries into 
patients’ pastimes. Patients complaining of sleep disturbance 
should also be asked speciﬁ  cally how they cope with periods 
of sleep deprivation. Punding may also be suspected if the 
addition of further dopaminergic therapy at night exacerbates 
rather than beneﬁ  ts patient’s insomnia. In the study by Evan 
and colleagues (2004), patients with L-DOPA equivalent units 
(LEU) greater than or equal to 800 were recruited. Of these, 
punders were more likely to use apomorphine and cabergoline, 
and less likely to use entacapone. Increasing clinical severity of 
the punding behavior signiﬁ  cantly correlated with higher total 
daily LEU dose, younger age, reduced sleep time overnight, 
and average number of daily rescue doses suggesting patients 
with punding may have dopa dysregulation.
Pathological gambling has been attributed by some to the 
use of dopamine agonists, but this putative association has 
not been conﬁ  rmed (Driver-Dunckley et al 2003; Dodd et al 
2005). Younger age at PD onset, higher novelty seeking traits, 
and a personal or family history of alcohol use disorders have 
been found to be associated with a greater risk for patho-
logical gambling with dopamine agonists (Voon et al 2007). 
Contrary to typical obsessive-compulsive disorders, punding 
and other ICDs respond poorly to SSRIs, clomipramine and 
antipsychotics (Evans et al 2004; Kurlan 2004). Treatment 
options such as decreasing the dose of DA, or switching to 
a different DA, produce the best results (Borek et al 2007; 
Miyasaki et al 2007).
Excessive daytime sleepiness (EDS), sleep fragmentation, 
altered dreaming and RBD affect over three-quarters of 
PD patients (Friedman and Chou 2004). The existence of 
other causes of EDS, such as obstructive sleep apnea, use of 
sedative medication and the presence of concurrent medical 
illnesses must be established and treated. Both pramipexole 
and ropinirole (and possibly other DA agonists) have been 
associated with irresistible sleep attacks leading to motor 
vehicle mishaps (Frucht et al 1999; Hauser et al 2000; 
Brodsky et al 2003). Sleepiness correlated signiﬁ  cantly with 
a longer duration of PD, more advanced PD, male gender, and 
the use of any DA (Ondo et al 2001). The soporiﬁ  c effects 
of the three most common DA (pramipexole, ropinirole, and 
pergolide) and even levodopa were similar (Ondo et al 2001; 
Brodsky et al 2003). The risk of accidents can be prevented by 
discussing this potential side effect with the patient and their 
family, by warning them not to drive if they feel drowsy, and 
by encouraging them to take short naps on the side of the road 
as needed (Reyner and Horne 1998). Modaﬁ  nil (Provigil®) at 
100 to 200 mg twice a day is effective in reversing the exces-
sive daytime drowsiness and the sedative effects of anti-PD 
medications (Hauser et al 2000; Ondo et al 2001), although 
a recent double-blind, placebo-controlled study failed to 
signiﬁ  cantly improve EDS in PD patients when compared to 
placebo (Ondo et al 2005b). Vivid and often violent dreams, 
with prominent motor activity and loss of normal atonia dur-
ing REM sleep characterize RBD. TCAs, SSRIs and MAO 
inhibitors can induce or aggravate RBD. Clonazepam is 
considered the treatment of choice with effectiveness in about 
90% of patients (Gagnon et al 2006).
The nonmotor side effects of levodopa, such as 
hallucinations and orthostatic hypotension, are dose-related 
and these adverse effects could offset the potential beneﬁ  ts 
of prolonged motor response. In addition to adjusting 
levodopa dosing, reductions of anticholinergic drugs may 
also ameliorate dyskinesias. Dystonia often improves with 
the administration of baclofen, anticholinergic drugs, DA 
agonists, lithium, and local injections of botulinum toxin.
Neurosurgical treatments 
of Parkinson’s disease
It is beyond the scope of this manuscript to comprehensively 
review neurosurgical treatment of PD. Only a brief review Neuropsychiatric Disease and Treatment 2008:4(4) 753
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will be provided here and the reader is referred to other 
published literature on for additional information about 
this important therapeutic strategy. The renewed interest in 
surgical treatment of movement disorders has been stimu-
lated in part by improved understanding of the functional 
anatomy underlying motor control, as well as reﬁ  nement of 
methods and techniques in neurosurgery, neurophysio  logy, 
and neuroimaging (Jankovic 2001; Krauss et al 2001).
Besides thalamotomy and pallidotomy, another promis-
ing surgical approach for the treatment of tremors and other 
movement disorders is high-frequency DBS via electrodes 
implanted in the VIM nucleus of the thalamus, GPi, STN or 
other subcortical nuclei. The mechanism of electrical stimula-
tion is not known, but the following explanations have been 
offered: 1) disruption of the network (“jamming” of feedback 
loop from the periphery), 2) depolarization block, 3) prefer-
ential activation of inhibitory neurons, and 4) a functional 
ablation by desynchronizing a tremorogenic pacemaker.
Thalamic stimulation appears to be particularly effective 
in the treatment of parkinsonian tremor and ET. Our experi-
ence at Baylor is similar to that reported in other centers. In a 
blinded and open label trial of unilateral thalamic DBS in 33 
patients (14 ET and 19 PD) with severe tremor refractory to 
conventional therapy, both groups of patients demonstrated 
a statistically signiﬁ  cant decrease (p  0.0001) in observed 
contralateral arm tremor, respectively (Ondo et al 1998). 
All measures of tremor, including writing samples, pouring 
tests, subjective functional surveys, and disability scores 
signiﬁ  cantly improved. To compare thalamic DBS with 
thalamotomy, Schuurman and colleagues (2000) conducted a 
prospective, randomized study of 68 patients with PD, 13 with 
ET, and 10 with multiple sclerosis. They found that the func-
tional status improved more in the DBS group as compared 
to the thalamotomy group and tremor was suppressed com-
pletely or almost completely in both the DBS group and in the 
thalamotomy group. Although one patient in the DBS group 
died after an intracerebral hemorrhage, DBS was associated 
with signiﬁ  cantly fewer complications than thalamotomy. In 
addition to improving distal tremor associated with PD and 
ET, VIM DBS can effectively control ET head tremor, which 
usually does not respond to conventional therapy.
Since bilateral thalamotomy can cause hypophonia, 
dysarthria, and dysphagia, DBS is now considered the best 
alternative, particularly in those patients who require bilateral 
procedures. Thalamotomy has the advantage over DBS in that 
there is no need for hardware, and for patients with disabling 
bilateral tremor, unilateral thalamotomy in combination with 
contralateral DBS may offer the optimal tremor control with 
the fewest adverse side effects. Chronic stimulation of the 
thalamus appears to be well tolerated and the risk of local 
gliosis is minimal (Haberler et al 2000), although more 
extensive damage has been rarely reported (Henderson et al 
2002). Because of the ability to customize the stimulation 
parameters and the relatively low risk of complications, 
DBS is now considered the preferred surgical treatment for 
disabling PD-related tremor or ET.
Several studies have demonstrated that DBS of the GPi 
and STN improves parkinsonian symptoms and prolongs 
the “on” time (Linizasaro 2003), as well as other aspects of 
quality of life (Diamond and Jankovic 2005). The relative 
safety and efﬁ  cacy of STN vs GPi DBS, however, has been 
compared formerly in only small studies (Burchiel et al 
1999). Although no difference between the two targets 
was found by Burchiel, their study had insufﬁ  cient power 
to detect a difference between the two groups. The “off” 
UPDRS motor score has been reported to improve by 34% 
to 60% and the UPDRS ADL score by 30%–50% in patients 
undergoing STN or GPi DBS. Furthermore, dyskinesia has 
been reported to markedly improve, largely as a result of 
about 50% reduction in daily levodopa dosage.
Both STN and GPi DBS improve the off medication 
UPDRS motor score (Anderson et al 2005), worsen the 
“on” motor states of the motor UPDRS, activities of daily 
living and gait, and improve the “off” medication UPDRS 
respect to the baseline (Rodriguez-Oroz et al 2005). Neither 
the STN nor the GPi DBS improves the “on” medication 
function. In a ﬁ  ve year follow up after bilateral STN DBS 
on the ﬁ  rst 49 consecutive patients, Krack and colleagues 
(2003) found marked improvement in motor function while 
off medications and in dyskinesia while on medications. 
At ﬁ  ve years, the LEU dose and the duration and severity 
of levodopa-induced dyskinesia were reduced compared 
to baseline. In a study of 30 patients with PD Hoehn and 
Yahr stages 3–4 while off medication randomized to either 
STN or GPi DBS, 89% improvement of dyskinesias in 
the GPi DBS group was observed, while in the STN DBS 
group, dyskinesias improved by 62% (Anderson et al 2003). 
Bradykinesia improved more in the STN group when com-
pared to GPi stimulation (Anderson et al 2003), and STN 
DBS was associated to a greater decrease in levodopa dos-
age (Rodriguez-Oroz et al 2005), but more severe speech 
impairment, postural instability, and cognitive decline 
(Anderson et al 2003; Rodriguez-Oroz et al 2005). Since 
improvements in dyskinesia usually require a reduction in 
levodopa dosage, unilateral STN or GPi DBS is impractical 
because the side of the body contralateral to the unstimulated Neuropsychiatric Disease and Treatment 2008:4(4) 754
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side would clearly worsen. Bilateral STN DBS appears to 
be more effective than unilateral STN DBS in improving 
Parkinsonism, but unilateral STN DBS may be appropri-
ate for patients with asymmetric parkinsonian symptoms 
including a high amplitude tremor (Kumar et al 1999; Stover 
et al 2005b; Diamond et al 2007). In addition to improving 
limb signs and the cardinal signs of PD, bilateral STN DBS 
has been found to also improve axial parkinsonian symp-
toms, particularly arising from chair and gait, but speech, 
neck rigidity, abnormal posture, and postural instability also 
improved (Bejjani et al 2000).
Except for mild deﬁ  cit in lexical ﬂ  uency, STN or GPi DBS 
does not appear to adversely affect cognitive performance 
(Pillon et al 2000), but some older patients have been found 
to have an impairment in frontal executive function (Saint-
Cyr et al 2000). Although bilateral STN is clearly effective 
in improving the cardinal as well as other parkinsonian 
symptoms, the procedure does not necessarily improve all 
the symptoms and, as a result of progression of cognitive, 
speech, and other deﬁ  cits frequently associated with PD, the 
quality of life may not substantially improve in patients who 
exhibit these additional features (Hariz et al 2000).
Other therapeutic approaches
Besides conventional pharmacologic and surgical treatments, 
there are many other strategies currently being explored in the 
treatment of some PD symptoms (Jankovic 1999; Jankovic 
2001) (Table 4). Speech therapy designed to stimulate 
increased vocal fold adduction with instructions to “increase 
loudness”, the so called Lee Silverman Voice Treatment 
(LSVT), using various verbal cues to regulate speech volume, 
and percutaneous collagen augmentation of the vocal folds 
(Hill et al 2003) have been used successfully to treat the 
hypophonic, hypokinetic dysarthria associated with PD.
Although this review has attempted to highlight the 
most recent advances in the treatment of PD, it is important 
to note that new treatments are not necessarily better than 
the established conventional therapy and that the treatment 
options must be individualized and tailored to the needs of 
each individual patient (Jankovic 2000, 2002b).
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